Welcome to our dedicated page for Day One Biopharmaceuticals SEC filings (Ticker: DAWN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on clinical data releases, financial results, and material corporate agreements for this commercial-stage biopharmaceutical company focused on targeted cancer therapies.
Day One uses Form 8-K to report material events such as updated three-year data from the pivotal FIREFLY-1 trial of OJEMDA™ (tovorafenib) in pediatric low-grade glioma, financial results for specific quarters, and changes to corporate presentations. For example, an 8-K dated November 24, 2025 describes FIREFLY-1 efficacy and safety outcomes, while other 8-Ks attach press releases and slide decks summarizing OJEMDA net product revenue, license revenue, operating expenses, and cash balances.
Filings also document transactional and corporate actions. An 8-K filed in November 2025 outlines the Agreement and Plan of Merger through which Day One agreed to acquire Mersana Therapeutics via a tender offer and subsequent merger, including the structure of cash consideration and contingent value rights. Another 8-K describes an option repricing approved by the board of directors, providing detail on how stock options for certain directors and employees are adjusted and conditioned on continued service.
Through these SEC documents, readers can examine how Day One reports clinical trial outcomes, such as response rates and treatment-free intervals from FIREFLY-1, as well as how it communicates financial performance and corporate governance decisions. Stock Titan’s interface surfaces these filings alongside AI-powered summaries that highlight key points, helping users quickly understand the context of each report while preserving access to the full underlying documents.
In addition to 8-Ks, investors may use this page as a starting point to locate Day One’s annual and quarterly reports, which provide broader overviews of its oncology pipeline, including OJEMDA, DAY301, and Emi-Le, and its status as a Nasdaq Global Select Market registrant under the symbol DAWN.
Jeremy Bender, Chief Executive Officer and director of Day One Biopharmaceuticals, Inc. (DAWN), reported vesting settlements of multiple Restricted Stock Units (RSUs) on 08/15/2025 that converted into common shares and a subsequent sale on 08/18/2025. The Form 4 shows acquisitions by settlement: 3,562, 4,750, 11,687 and 11,687 RSUs converting to common stock. On 08/18/2025 the filing reports a sale of 16,058 shares at a weighted average price of $6.7671, disclosed as executed to cover the reporting person's tax liability from RSU settlement. The filing also discloses significant indirect holdings across several trusts, including 1,408,285 shares held in the Bender Revocable Trust.
Lauren Merendino, Chief Commercial Officer of Day One Biopharmaceuticals, Inc. (DAWN), reported receipt and partial sale of company shares tied to vested restricted stock units (RSUs). On 08/15/2025 she was treated as acquiring multiple blocks of common stock through vesting of RSUs (3,162; 3,687; 3,687 shares) and the related derivative entries show those RSUs underlie the same share amounts. Following these transactions her reported beneficial ownership figures adjusted across several lines, and on 08/18/2025 she sold 3,766 shares in a block trade at a weighted average price of $6.7671 to cover taxes on RSU settlement.
The filing notes the RSUs represent one share each upon settlement for no consideration, vesting schedules (initial 1/4 on 08/15/2024 with remaining quarterly vesting, and separate 1/16 quarterly vesting for another award) and that RSU sales were solely to cover tax liabilities. The form was filed by one reporting person via attorney-in-fact.
Day One Biopharmaceuticals (DAWN) filed a Form 144 reporting a proposed sale of 16,058 common shares acquired as restricted stock from the issuer on 08/15/2025. The sale is to be effected through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value reported as $108,666.09 and the issuer's total shares outstanding listed as 102,431,933.
The notice records the approximate sale date as 08/18/2025, states no securities were sold by the reporting person in the past three months, and includes the standard representation that the seller is not aware of undisclosed material adverse information. Payment and acquisition details show the shares were issued and paid on 08/15/2025 and described as not applicable for other payment types.
Day One Biopharmaceuticals, Inc. (DAWN) Schedule 13G/A reports that RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and two individuals, Peter Kolchinsky and Rajeev Shah, each disclose 0.00 shares beneficially owned as of June 30, 2025, representing 0.0% of the company’s common stock. The filing lists the reporting persons' citizenships and principal business address and confirms the reporting status and classifications (IA, PN, HC, IN). The report includes a certification that the securities were not acquired to influence control. A Joint Filing Agreement is incorporated by reference.
Day One Biopharmaceuticals reported insider trading activity for Michael Vasconcelles, Head of Research and Development, who received significant equity compensation on June 16, 2025:
- Stock Options: Granted 346,000 options to purchase common stock at $6.64 per share, vesting over 4 years (25% after first year, then monthly)
- Restricted Stock Units (RSUs): Awarded 226,000 RSUs with zero exercise price, vesting over approximately 4 years (25% in August 2026, remaining quarterly)
The equity grants suggest a long-term retention strategy for this key executive, with the options expiring June 15, 2035. The combined award of performance-based options and time-vested RSUs represents a significant compensation package aimed at aligning the executive's interests with shareholders while providing both upside potential and guaranteed value through RSUs.
Day One Biopharmaceuticals (DAWN) has filed a Form 3 (Initial Statement of Beneficial Ownership) for Michael Vasconcelles, who has joined the company as Head of Research and Development. The filing date is June 28, 2025, with the triggering event occurring on June 16, 2025.
Key details of the filing:
- The reporting person currently owns no securities (derivative or non-derivative) of the company
- The filing is made individually, not as part of a group
- The reporting person serves as an Officer (Head of Research and Development) but is not a Director or 10% Owner
- The form was signed by Charles N. York II as Attorney-in-Fact on June 18, 2025
This Form 3 filing is a standard regulatory requirement for new officers under Section 16(a) of the Securities Exchange Act of 1934, establishing a baseline for future transactions and holdings reporting.